2014 Q3 Form 10-Q Financial Statement

#000114420414048884 Filed on August 12, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $1.162M $1.025M $291.5K
YoY Change 31.98% 251.53% 782.16%
Cost Of Revenue $475.9K $666.2K $199.6K
YoY Change -23.32% 233.82% 1879.71%
Gross Profit $686.5K $358.5K $91.93K
YoY Change 163.95% 289.98% 25.99%
Gross Profit Margin 59.06% 34.99% 31.54%
Selling, General & Admin $1.240M $1.209M $600.8K
YoY Change 80.36% 101.21% 104.93%
% of Gross Profit 180.71% 337.21% 653.57%
Research & Development $880.3K $347.0K $708.2K
YoY Change 199.22% -51.0% -1.06%
% of Gross Profit 128.24% 96.79% 770.34%
Depreciation & Amortization $20.00K $30.00K $20.00K
YoY Change 0.0% 50.0% 100.0%
% of Gross Profit 2.91% 8.37% 21.76%
Operating Expenses $2.170M $1.722M $1.499M
YoY Change 90.37% 14.89% 38.46%
Operating Profit -$1.484M -$1.363M -$1.407M
YoY Change 68.62% -3.09% 39.36%
Interest Expense -$46.60K -$127.8K -$8.147K
YoY Change -45.14% 1468.3% -78.45%
% of Operating Profit
Other Income/Expense, Net -$14.80K -$490.2K -$8.147K
YoY Change -82.58% 5917.1% -78.45%
Pretax Income -$1.498M -$1.854M -$1.415M
YoY Change 55.3% 31.0% 35.11%
Income Tax
% Of Pretax Income
Net Earnings -$1.498M -$1.854M -$1.415M
YoY Change 55.3% 31.0% 35.11%
Net Earnings / Revenue -128.91% -180.9% -485.44%
Basic Earnings Per Share -$0.27
Diluted Earnings Per Share -$120.0K -$0.27 -$152.3K
COMMON SHARES
Basic Shares Outstanding 310.7M shares 12.05M shares 229.9M shares
Diluted Shares Outstanding 12.05M shares

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.800M $9.600M $1.900M
YoY Change 239.13% 405.26% 11.76%
Cash & Equivalents $433.4K $4.878M $1.871M
Short-Term Investments $7.300M $4.700M
Other Short-Term Assets $200.0K $400.0K $200.0K
YoY Change -71.43% 100.0% 100.0%
Inventory $387.1K $303.7K $476.6K
Prepaid Expenses
Receivables $600.0K $300.0K $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.954M $10.62M $2.587M
YoY Change 145.73% 310.62% 4.88%
LONG-TERM ASSETS
Property, Plant & Equipment $191.1K $172.0K $142.7K
YoY Change 33.16% 20.54% 0.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $481.0K $462.6K $251.4K
YoY Change 91.33% 83.98% -12.46%
Total Long-Term Assets $672.1K $634.6K $394.1K
YoY Change 70.19% 61.02% -8.28%
TOTAL ASSETS
Total Short-Term Assets $8.954M $10.62M $2.587M
Total Long-Term Assets $672.1K $634.6K $394.1K
Total Assets $9.627M $11.26M $2.981M
YoY Change 138.34% 277.62% 2.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $446.2K $526.0K $720.6K
YoY Change -22.0% -27.01% 16.06%
Accrued Expenses $400.0K $600.0K $500.0K
YoY Change -20.0% 20.0% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $700.0K $900.0K
YoY Change -100.0% -22.22% -25.0%
Total Short-Term Liabilities $1.549M $2.769M $2.104M
YoY Change -49.46% 31.62% -8.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.549M $2.769M $2.104M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.500M $2.800M $2.104M
YoY Change -51.07% 33.08% -8.69%
SHAREHOLDERS EQUITY
Retained Earnings -$113.9M
YoY Change
Common Stock $322.8K $310.4K $234.4K
YoY Change 31.67% 32.42% 17.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.80M -$9.230M -$13.19M
YoY Change
Total Liabilities & Shareholders Equity $9.627M $11.26M $2.981M
YoY Change 138.34% 277.62% 2.93%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$1.498M -$1.854M -$1.415M
YoY Change 55.3% 31.0% 35.11%
Depreciation, Depletion And Amortization $20.00K $30.00K $20.00K
YoY Change 0.0% 50.0% 100.0%
Cash From Operating Activities -$1.930M -$1.460M -$1.020M
YoY Change 244.64% 43.14% -11.3%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K -$90.00K -$40.00K
YoY Change 500.0% 125.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.600M $0.00
YoY Change
Cash From Investing Activities -$2.670M -$90.00K -$40.00K
YoY Change 26600.0% 125.0% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K 10.00K 1.560M
YoY Change -97.03% -99.36% 41.82%
NET CHANGE
Cash From Operating Activities -1.930M -1.460M -1.020M
Cash From Investing Activities -2.670M -90.00K -40.00K
Cash From Financing Activities 30.00K 10.00K 1.560M
Net Change In Cash -4.570M -1.540M 500.0K
YoY Change -1138.64% -408.0% -814.29%
FREE CASH FLOW
Cash From Operating Activities -$1.930M -$1.460M -$1.020M
Capital Expenditures -$60.00K -$90.00K -$40.00K
Free Cash Flow -$1.870M -$1.370M -$980.0K
YoY Change 240.0% 39.8% -13.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
638746 USD
CY2013Q4 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
361700 USD
CY2014Q1 ctso Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
16575000 USD
CY2014Q1 ctso Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
2762500 USD
ctso Change In Fair Value Of Management Units
ChangeInFairValueOfManagementUnits
USD
ctso Change In Fair Value Of Management Units
ChangeInFairValueOfManagementUnits
USD
ctso Change In Fair Value Of Management Units
ChangeInFairValueOfManagementUnits
278087 USD
ctso Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest
CommonStockIssuedAsInducementToConvertConvertibleNotesPayableAndAccruedInterest
USD
ctso Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest
CommonStockIssuedAsInducementToConvertConvertibleNotesPayableAndAccruedInterest
USD
ctso Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest
CommonStockIssuedAsInducementToConvertConvertibleNotesPayableAndAccruedInterest
3351961 USD
ctso Consulting Fees
ConsultingFees
USD
ctso Consulting Fees
ConsultingFees
USD
ctso Consulting Fees
ConsultingFees
237836 USD
CY2014Q2 ctso Convertible Notes Current Unamortized Discount
ConvertibleNotesCurrentUnamortizedDiscount
35662 USD
CY2013Q4 ctso Convertible Notes Current Unamortized Discount
ConvertibleNotesCurrentUnamortizedDiscount
198644 USD
CY2014Q1 ctso Convertible Preferred Stock Conversion Price
ConvertiblePreferredStockConversionPrice
0.25
ctso Debt Discount
DebtDiscount
USD
ctso Debt Discount
DebtDiscount
188468 USD
ctso Debt Discount
DebtDiscount
1975322 USD
CY2013Q3 ctso Debt Instrument Maturity Period
DebtInstrumentMaturityPeriod
P1Y
CY2013Q2 ctso Debt Instrument Maturity Period
DebtInstrumentMaturityPeriod
P1Y
CY2013Q3 ctso Debt Instrument Percent Of Principal Amount
DebtInstrumentPercentOfPrincipalAmount
0.5 pure
CY2013Q2 ctso Debt Instrument Percent Of Principal Amount
DebtInstrumentPercentOfPrincipalAmount
0.5 pure
ctso Dividends Preferred Stock Series B
DividendsPreferredStockSeriesB
-2471488 USD
ctso Fair Value Warranty Liability Upon Issuance
FairValueWarrantyLiabilityUponIssuance
862920 USD
ctso Fair Value Warranty Liability Upon Issuance
FairValueWarrantyLiabilityUponIssuance
USD
ctso Fair Value Warranty Liability Upon Issuance
FairValueWarrantyLiabilityUponIssuance
862920 USD
ctso Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
1185840 USD
ctso Management Units Issued
ManagementUnitsIssued
USD
ctso Management Units Issued
ManagementUnitsIssued
USD
ctso Management Units Issued
ManagementUnitsIssued
437206 USD
CY2014Q2 ctso Number Of Patents Issued
NumberOfPatentsIssued
32 pure
ctso Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
2488761 USD
ctso Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
1202905 USD
ctso Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
15806316 USD
CY2014Q1 ctso Preferred Stock Conversion Percent Of Stated Value
PreferredStockConversionPercentOfStatedValue
0 pure
CY2014Q2 ctso Preferred Stock Value Not Included In Stockholders Equity
PreferredStockValueNotIncludedInStockholdersEquity
17717838 USD
ctso Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
5395250 shares
CY2013Q4 ctso Preferred Stock Value Not Included In Stockholders Equity
PreferredStockValueNotIncludedInStockholdersEquity
15246350 USD
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeited In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
0.031
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeituresInPeriod
4561250 shares
CY2014Q2 ctso Share Based Compensation Arrangement By Sharebased Payment Award Nonvested Options Grant Date Fair Value
ShareBasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsGrantDateFairValue
791000 USD
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Granted In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantedInPeriodWeightedAverageGrantDateFairValue
0.058
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriod
15775000 shares
CY2014Q2 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber
22344500 shares
CY2013Q4 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber
13418000 shares
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriod
2287250 shares
ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.044
ctso Share Based Compensation Arrangement By Share Based Payment Award Non Vested Options Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedOptionsVestedNumber
14010000 shares
CY2014Q2 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue
0.051
CY2013Q4 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue
0.034
ctso Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm
P8Y
CY2014Q2 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableAggregateIntrinsicValue
4268000 USD
ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P9Y4M24D
ctso Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2013 ctso Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y1M6D
ctso Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
10200000 USD
ctso Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
USD
ctso Supplemental Noncash Transactions
SupplementalNoncashTransactions
748545 USD
ctso Supplemental Noncash Transactions
SupplementalNoncashTransactions
USD
ctso Supplemental Noncash Transactions
SupplementalNoncashTransactions
1516608 USD
ctso Technology And Content Expense
TechnologyAndContentExpense
USD
ctso Technology And Content Expense
TechnologyAndContentExpense
USD
ctso Technology And Content Expense
TechnologyAndContentExpense
4550000 USD
CY2013Q3 ctso Warrant Exercise Price
WarrantExercisePrice
0.10
CY2013Q2 ctso Warrant Exercise Price
WarrantExercisePrice
0.15
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001175151
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
310699452 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
Cytosorbents Corp
dei Trading Symbol
TradingSymbol
ctso
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
525957 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
786517 USD
CY2014Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
330347 USD
CY2013Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
453017 USD
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-50836 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-55987 USD
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101631678 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
91343135 USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
533648 USD
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
104858 USD
us-gaap Advertising Expense
AdvertisingExpense
63000 USD
us-gaap Advertising Expense
AdvertisingExpense
10000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
105000 USD
CY2014Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1801 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
162982 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
181350 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2939959 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
183556 USD
CY2014Q2 us-gaap Assets
Assets
11257021 USD
CY2013Q4 us-gaap Assets
Assets
4045735 USD
CY2014Q2 us-gaap Assets Current
AssetsCurrent
10622443 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
3486967 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
20400000 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
41601616 shares
CY2014Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
634578 USD
CY2013Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
558768 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0px" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify"> <td style="FONT: 10pt Times New Roman, Times, Serif; TEXT-ALIGN: left; WIDTH: 0.25in"> <strong>1.</strong></td> <td style="FONT: 10pt Times New Roman, Times, Serif; TEXT-ALIGN: justify"> <strong>BASIS OF PRESENTATION</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The accompanying unaudited interim consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q of the Securities and Exchange Commission (the "Commission") and include the results of CytoSorbents Corporation (the "Parent"), CytoSorbents, Inc., its wholly-owned operating subsidiary (the "Subsidiary"), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the "European Subsidiary"), collectively referred to as "the Company."</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> Accordingly, certain information and footnote disclosures required in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. Interim statements are subject to possible adjustments in connection with the annual audit of the Company&#39;s accounts for the year ended December 31, 2014. In the opinion of the Company&#39;s management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) which the Company considers necessary for the fair presentation of the Company&#39;s consolidated financial position as of June 30, 2014 and the results of its operations and cash flows for the six and three month periods ended June 30, 2014 and 2013, and for the period January 22, 1997 (date of inception) to June 30, 2014. Results for the six months ended June 30, 2014 and 2013 are not necessarily indicative of results that may be expected for the entire year. The unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements of the Company and the notes thereto as of and for the year ended December 31, 2013 as included in the Company&#39;s Form 10-K filed with the Commission on March 31, 2014.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has experienced negative cash flows from operations since inception and has a deficit accumulated during the development stage at June 30, 2014 of $111,123,221. The Company is not currently generating significant revenue and is dependent on the proceeds of present and future financings to fund its research, development and commercialization program. The Company currently has adequate funding for more than the next twelve months of operations; however, it may have to raise additional capital to fund future operations. Although the Company has historically been successful in raising additional capital through equity and debt financings, there can be no assurance that the Company will be successful in raising additional capital in the future or that it will be on favorable terms. Furthermore, if the Company is successful in raising the additional financing, there can be no assurance that the amount will be sufficient to complete the Company&#39;s plans. These matters raise substantial doubt about the Company&#39;s ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The Company is a development stage company and has generated limited revenues. Since inception, the Company&#39;s expenses relate primarily to research and development, organizational activities, clinical manufacturing, regulatory compliance and operational strategic planning. Although the Company has made advances on these matters, there can be no assurance that the Company will continue to be successful regarding these issues, nor can there be any assurance that the Company will successfully implement its long-term strategic plans.</p> <!--EndFragment--></div> </div>
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4878446 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2183030 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1870612 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1729344 USD
CY1997Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2695416 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
141268 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4878446 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2014Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
20400000 shares
CY2014Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1601070 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
310399452 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
251319547 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
310399452 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
251319547 shares
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
310399 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
251320 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2823534 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1849284 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3047200 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1415856 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-95367741 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Concentration of Credit Risk</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> As of June 30, 2014, one U.S. government agency, two distributors, and two hospitals accounted for approximately 74.2% of outstanding grant and accounts receivable. At December 31, 2013, one U.S. government agency accounted for approximately 66% of outstanding accounts receivable. For the six months ended June 30, 2014, approximately 11.5% of revenues were from one U.S. government agency, and no other agency, distributor, or direct customer represented more than 10% of the Company&#39;s revenue. For the six months ended June 30, 2013, approximately 44.9% of revenue was from one U.S. government grant agency.</p> <!--EndFragment--></div> </div>
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
559 USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
399395 USD
CY2014Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
40800000 shares
CY2014Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
20400000 shares
CY2013Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1511883 USD
CY2014Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
745000 USD
CY2014Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
709338 USD
CY2013Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1644356 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1328688 USD
CY2014Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
666151 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
453066 USD
CY2013Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
199555 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
4074124 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1185840 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1226042 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
14361331 USD
CY2014Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
10200000 USD
CY2013Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
7450000 shares
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
9486720 shares
CY2013 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
160105 USD
CY2013Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.125
CY2013Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.125
CY2013Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
745000 USD
CY2013Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1098000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
272359 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
45596 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
31585 USD
CY2013Q3 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2013Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2014Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
36000 USD
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5833 USD
CY2014Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
CY2014Q2 us-gaap Gross Profit
GrossProfit
358504 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2613967 USD
CY2014Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
111123221 USD
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
105805775 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
5151 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3269 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-50836 USD
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
196000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
26520 USD
CY2014Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
342720 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
26520 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
CY2014Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
CY2013Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
21663 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
CY2013Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
216617 USD
us-gaap Gross Profit
GrossProfit
758139 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
162428 USD
us-gaap Gross Profit
GrossProfit
209747 USD
CY2013Q2 us-gaap Gross Profit
GrossProfit
91928 USD
us-gaap Gross Profit
GrossProfit
2814829 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2828685 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1853602 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3043931 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1414989 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-96714258 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1397353 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
104326 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3328878 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-122670 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32286 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
330347 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-266526 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5833 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1823103 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
58078 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-205822 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
303686 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4912 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-9442 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
58807 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-240348 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-320420 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
636512 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
163000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
181000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-264858 USD
CY2014Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-127769 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-214859 USD
CY2013Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8147 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-7989251 USD
us-gaap Interest Paid
InterestPaid
USD
us-gaap Interest Paid
InterestPaid
USD
us-gaap Interest Paid
InterestPaid
590189 USD
CY2014Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
115000 USD
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
107000 USD
CY2014Q2 us-gaap Inventory Net
InventoryNet
303686 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
245608 USD
CY2014Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
18000 USD
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
38000 USD
CY2014Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
170000 USD
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
101000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
90100 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
65468 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
185568 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11257021 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4045735 USD
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2769314 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3064932 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9812560 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2013067 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86470110 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4861494 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35318 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9596851 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2260801 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1833212 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-71943977 USD
us-gaap Net Income Loss
NetIncomeLoss
-2828685 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-1853602 USD
us-gaap Net Income Loss
NetIncomeLoss
-3043931 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-1414989 USD
us-gaap Net Income Loss
NetIncomeLoss
-95316905 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5317446 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3227847 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4246836 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2031477 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-111123221 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-291378 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-470489 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-214859 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8147 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8138986 USD
us-gaap Operating Expenses
OperatingExpenses
3295446 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
1741617 USD
us-gaap Operating Expenses
OperatingExpenses
3038819 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
1498770 USD
us-gaap Operating Expenses
OperatingExpenses
91390101 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2537307 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1383113 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2829072 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1406842 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-88575272 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
USD
us-gaap Other Noncash Expense
OtherNoncashExpense
USD
us-gaap Other Noncash Expense
OtherNoncashExpense
361496 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
CY2014Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
USD
us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
USD
us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
74938 USD
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
462588 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
414375 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5151 USD
CY2014Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4318 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3269 USD
CY2013Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-867 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-50836 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5151 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
CY2013Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
361495 USD
us-gaap Other Operating Income
OtherOperatingIncome
USD
CY2014Q2 us-gaap Other Operating Income
OtherOperatingIncome
USD
us-gaap Other Operating Income
OtherOperatingIncome
USD
CY2013Q2 us-gaap Other Operating Income
OtherOperatingIncome
USD
us-gaap Other Operating Income
OtherOperatingIncome
6055483 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
4167 USD
CY2014Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
2500 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
USD
CY2013Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
4167 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
USD
us-gaap Paid In Kind Interest
PaidInKindInterest
USD
us-gaap Paid In Kind Interest
PaidInKindInterest
3147 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
61760 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
12769 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
737946 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
4745000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
5138607 USD
us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
USD
us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
USD
us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
1632168 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54734 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22549 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2514228 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2488761 USD
CY2014Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1374245 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1202905 USD
CY2013Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
616488 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
15806316 USD
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
1849 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
1760 USD
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
364964 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
605312 USD
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
9751455 USD
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
899967 USD
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
62423223 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9451000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
9579040 USD
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
USD
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
1098000 USD
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
13731881 USD
CY2013 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
1843000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
499395 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
393607 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
32491 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61105 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15100 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
97045 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
139526 USD
CY2014Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
889440 USD
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
USD
us-gaap Professional Fees
ProfessionalFees
550060 USD
CY2014Q2 us-gaap Professional Fees
ProfessionalFees
239752 USD
us-gaap Professional Fees
ProfessionalFees
412539 USD
CY2013Q2 us-gaap Professional Fees
ProfessionalFees
189793 USD
us-gaap Professional Fees
ProfessionalFees
10043839 USD
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
171990 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
144393 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
255882 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
583767 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
346993 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1412300 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
708159 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56252164 USD
us-gaap Revenue From Grants
RevenueFromGrants
850184 USD
CY2014Q2 us-gaap Revenue From Grants
RevenueFromGrants
358922 USD
us-gaap Revenue From Grants
RevenueFromGrants
358746 USD
CY2013Q2 us-gaap Revenue From Grants
RevenueFromGrants
163514 USD
us-gaap Revenue From Grants
RevenueFromGrants
4642871 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1232476 USD
CY2014Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
663233 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
304067 USD
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
127969 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2241915 USD
us-gaap Sales Revenue Net
SalesRevenueNet
2086827 USD
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
1024655 USD
us-gaap Sales Revenue Net
SalesRevenueNet
662813 USD
CY2013Q2 us-gaap Sales Revenue Net
SalesRevenueNet
291483 USD
us-gaap Sales Revenue Net
SalesRevenueNet
6888953 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2161619 USD
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1154872 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1213980 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
600818 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31149581 USD
us-gaap Service Management Costs
ServiceManagementCosts
USD
us-gaap Service Management Costs
ServiceManagementCosts
USD
us-gaap Service Management Costs
ServiceManagementCosts
1334285 USD
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.3125
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.3125
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.3125
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.283 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.283 pure
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
47923642 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.21
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.20
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0162 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0162 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1616300 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
51809 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
15775000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
56635283 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.12
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.20
CY2014Q2 us-gaap Share Price
SharePrice
0.242
CY2014Q1 us-gaap Share Price
SharePrice
0.240
us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
48000 USD
us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
13000 USD
CY2014Q2 us-gaap Short Term Investments
ShortTermInvestments
4745000 USD
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
-9230131 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-14265547 USD
us-gaap Stock Issued1
StockIssued1
7137 USD
us-gaap Stock Issued1
StockIssued1
10413 USD
us-gaap Stock Issued1
StockIssued1
640270 USD
us-gaap Use Of Estimates
UseOfEstimates
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Use of Estimates</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends, valuation methods used to determine the fair value of the warrant liability, and valuation methods used in determining any debt discount associated with convertible securities.</p> <!--EndFragment--></div> </div>
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
750000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1616300 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
90100 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
300000 USD
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-748545 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
61105 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
104858 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
266490 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3129983 USD
CY2013Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
171012 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
283424589 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
301195959 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
227299644 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
231583119 shares

Files In Submission

Name View Source Status
0001144204-14-048884-index-headers.html Edgar Link pending
0001144204-14-048884-index.html Edgar Link pending
0001144204-14-048884.txt Edgar Link pending
0001144204-14-048884-xbrl.zip Edgar Link pending
ctso-20140630.xml Edgar Link completed
ctso-20140630.xsd Edgar Link pending
ctso-20140630_cal.xml Edgar Link unprocessable
ctso-20140630_def.xml Edgar Link unprocessable
ctso-20140630_lab.xml Edgar Link unprocessable
ctso-20140630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v385566_10q.htm Edgar Link pending
v385566_ex31-1.htm Edgar Link pending
v385566_ex31-2.htm Edgar Link pending
v385566_ex32-1.htm Edgar Link pending
v385566_ex32-2.htm Edgar Link pending